Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
<h4>Objectives</h4>Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Most cases are diagnosed at an advanced stage using current tumor markers. Here, we aimed to identify potential novel potential biomarkers for NSCLC.<h4>Material/methods</h4...
Main Authors: | Dandan Zhou, Xiuming Zhai, Ruixue Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0291461 |
Similar Items
-
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
by: Pei-Ming Yang, et al.
Published: (2020-01-01) -
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
by: Guanggai Xia, et al.
Published: (2017-08-01) -
Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
by: Zanwen Zuo, et al.
Published: (2024-01-01) -
Regulatory Role of Ribonucleotide Reductase Subunit M2 in Hepatocyte Growth and Pathogenesis of Hepatitis C Virus
by: Bouchra Kitab, et al.
Published: (2023-01-01) -
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
by: Ying Z. Mazzu, et al.
Published: (2020-08-01)